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Therapeutic Manipulation of miRNA in
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MaBACKGROUND Drug-eluting stents reduce the incidence of in-stent restenosis, but they result in delayed arterial
healing and are associated with a chronic inflammatory response and hypersensitivity reactions. Identifying novel in-
terventions to enhance wound healing and reduce the inflammatory response may improve long-term clinical outcomes.
Micro–ribonucleic acids (miRNAs) are noncoding small ribonucleic acids that play a prominent role in the initiation and
resolution of inflammation after vascular injury.
OBJECTIVES This study sought to identify miRNA regulation and function after implantation of bare-metal and drug-
eluting stents.
METHODS Pig, mouse, and in vitro models were used to investigate the role of miRNA in in-stent restenosis.
RESULTS We documented a subset of inflammatory miRNAs activated after stenting in pigs, including the miR-21 stem
loop miRNAs. Genetic ablation of the miR-21 stem loop attenuated neointimal formation in mice post-stenting. This
occurred via enhanced levels of anti-inflammatory M2 macrophages coupled with an impaired sensitivity of smooth
muscle cells to respond to vascular activation.
CONCLUSIONS MiR-21 plays a prominent role in promoting vascular inflammation and remodeling after stent injury.
MiRNA-mediated modulation of the inflammatory response post-stenting may have therapeutic potential to accelerate
wound healing and enhance the clinical efficacy of stenting. (J Am Coll Cardiol 2015;65:2314–27) © 2015 by the
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AB BR E V I A T I O N S
AND ACRONYM S
BMDM = bone marrow–derived
macrophages
BMS = bare-metal stent(s)
CD = cluster of differentiation
DES = drug-eluting stent(s)
IL = interleukin
ISR = in-stent restenosis
KO = knockout
LPS = lipopolysaccharide
miRNA = micro–ribonucleic
acid
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2315patients treated with bare-metal stents (BMS) at 1
year. The development of metallic drug-eluting
stents (DES) coated with an antiproliferative drug
has substantially reduced ISR (5) but is associated
with a significantly greater incidence of late stent
thrombosis compared with BMS due to delayed arte-
rial healing (6,7). Several clinical trials are currently
evaluating fully bioresorbable nonmetallic DES, but
early reports suggest that they may have higher rates
of incomplete strut apposition and strut fracture
(8,9). Collectively, these findings highlight the need
to further improve our understanding of the events
that control vascular healing responses with both
BMS and DES.SEE PAGE 2328
PDCD4 = programmed cell
death protein 4
PDGF = platelet-derived
growth factor
PPAR = peroxisome
proliferator–activated receptor
RNA = ribonucleic acid
SMC = smooth muscle cell
WT = wild-typeNoncoding ribonucleic acids (RNAs) play a pivotal
role in many physiological and homeostatic processes
(10,11). The best characterized are short, highly
conserved RNA molecules called microRNAs (miR-
NAs), which mediate messenger RNA silencing
through translational degradation or repression after
complementary base pairing (12). More than 1,000
miRNAs are thought to regulate w30% of all protein-
coding messenger RNA (13). Thus, a single miRNA
may have $1 messenger RNA targets at different
points within multiple biological pathways to me-
diate a disease phenotype (14,15). In the setting of
vascular injury, miRNAs are involved in inflammatory
cell recruitment and activation and dedifferentiation
of SMCs, key processes that drive the vessel response
to injury. However, there has been no systematic
analysis of miRNA regulation post-stent deployment.
The goal of the present study, therefore, was to
define the expression pattern and function of miRNAs
after stenting with BMS and DES to identify miRNAs
with the potential to modulate vascular response to
injury.
METHODS
Detailed methods are available in the Online
Appendix. In brief, male Landrace pigs (19 to 26 kg)
were pre-dosed orally with aspirin and clopidogrel
24 h before surgery, and they were maintained on this
dual antiplatelet therapy throughout the study to
reduce the risk of in-stent thrombosis. Vascular ac-
cess was obtained by femoral artery cutdown and the
insertion of a 6-F transradial sheath (Arrow Interna-
tional, Reading, Pennsylvania). Coronary angiog-
raphy was performed before the deployment of
either BMS (Gazelle, Biosensors Europe SA, Morges,
Switzerland) or Biolimus A9 eluting stents (BioMatrix
Flex, Biosensors Europe SA) to achieve a target ratioof stent to artery diameter of 1.2:1. Animals
were euthanized after 7 or 28 days.
In the murine model, a stainless steel stent
(5-cell, 2.5 mm  0.8 mm; strut thickness
0.06 mm; Cambus Medical, Galway, Ireland)
was crimped onto a 1.20-mm  8-mm Mini-
Trek balloon angioplasty catheter (Abbott
Vascular, Abbott Park, Illinois) and deployed
(10 atm for 30 s) into the thoracic aorta before
engraftment into a recipient mouse. Mice
were allowed to recover in heated chambers
for 24 h and were returned to normal housing
conditions, where they were maintained on
aspirin-supplemented water and a normal
chow diet for another 28 days before being
killed. Murine aortas were harvested from
male mice 8 to 12 weeks of age, and vascular
SMCs were isolated and cultured. Cell
migration was assessed via scratch assay.
Bone marrow–derived macrophages (BMDM)
were generated and bone marrow cells iso-
lated from femurs and tibiae of wild-type
(WT) and miR-21 knockout (KO) mice. Flow
cytometry was performed by using a BD FACSCanto II
or LSR II (BD Biosciences, San Jose, California).
Global profiling for miRNAs in the control unsten-
ted arteries and stented porcine coronary arteries was
performed with miRNA quantification by using real-
time polymerase chain reaction. For analysis, fold
changes for each miRNA were normalized to U6
because this miRNA was the most suitable endo-
genous miRNA in porcine tissue. Data analysis
was performed by using SDS software version 2.3
(Applied Biosystems, Carlsbad, California), and the
baseline and threshold were automatically set. Data
were normalized and then analyzed to identify miR-
NAs differentially expressed between the control
(unstented) arteries and arteries subjected to stenting
for 7 or 28 days. Data were analyzed by using Data-
Assist software version 3 (Applied Biosystems).
All data are mean  SEM. Visual assessment was
used to check for any lack of normality; because there
was no evidence of this, 1-way analysis of variance
followed by a Tukey multiple comparison test (for
comparison of >2 groups) or Student t test (for
comparison of 2 groups) were conducted. For all
the quantitative polymerase chain reaction experi-
ments, values are expressed as fold-change. All sta-
tistical analyses were conducted by using Prism
version 4 (GraphPad Software, San Diego, California).
The microRNA array data were analyzed in DataAssist
software. Comparisons of in vitro SMC proliferation
and migration were performed by using 2-way anal-
ysis of variance and Bonferroni post-hoc tests.
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dance with the United KingdomHome Office Guidance
on the operation of the Animals (Scientific Procedures)
Act 1986 and institutional ethical approval.
RESULTS
The effects of BMS and DES on ISR were assessed in
pig coronary arteries by using optical coherence to-
mography imaging (Figures 1A to 1D). The DES
reduced neointima formation by 33% compared with
BMS at 28 days (Figure 1A), leading to a significantly
larger luminal area (Figure 1B) with no difference in
stent expansion (Figure 1C).
We sought to identify aberrantly expressed
miRNAs. At 7 days post-stenting, 116 miRNAs were
differentially regulated in the BMS group, with 23
miRNAs remaining dysregulated at 28 days. At
7 days, multiple miRNAs associated with inflamma-
tory cell infiltration and activation were altered
(Online Table 1, Online Figure 1). Of note, miR-21-3p
was substantially up-regulated in both BMS- and
DES-treated arteries at 7 days, suggesting that the
miR-21 stem loop (i.e., both lead and “passenger”
strands) may be important post-stenting. TheFIGURE 1 ISR Assessment: Porcine Stent Model
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validated, and this revealed that miR-21-5p was
significantly up-regulated in stented arteries at 7 days
regardless of stent type and remained up-regulated at
28 days compared with unstented control arteries
(Figure 2A). MiR-21-3p was also up-regulated at 7 and
28 days post-stenting in both groups (Figure 2B). We
then identified the localization of expression of the
miR-21 axis in the vessel wall after stenting, focusing
on miR-21-5p (because the absolute levels of miR-21-
3p are lower and below the detection threshold for
in situ hybridization). In control coronary arteries,
miR-21-5p was detected within the media (Figure 2C).
In injured vessels 28 days post-stenting, increased
signal intensity was observed in the medial layer and
developing neointima, particularly around stent
struts. To determine if this expression pattern is
maintained in the clinical setting, in situ hybridiza-
tion was performed in human coronary arteries 14
days post-stenting from tissue obtained from a heart
transplant patient. In concordance with the staining
pattern in porcine arteries, abundant miR-21 expres-
sion was observed in the developing neointima
and infiltrating inflammatory cells (Figure 2D,
Online Figure 2). Taken together, these findingsC
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FIGURE 2 Regulation of miR-21-5p and -3p During ISR
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2318suggest that miR-21-5p and miR-21-3p may be
important in the development of post-stent patho-
physiological responses to injury.
We used a murine interpositional graft model of
stenting. In situ hybridization confirmed abundant
miR-21-5p staining around the stent struts and
developing neointima (Figure 3), consistent with the
porcinedata.Morphometric analysis found thatmiR-21
KO mice stent grafts had a reduced neointimal
area, neointimal thickness, and neointima-to-medial
ratio compared with WT controls (1.37  0.18 [n ¼ 8]
vs. 2.11  0.17 [n ¼ 9]; p < 0.05) (Figures 4A and 4B,
Online Table 2). Measurements of strut depth were
concordant with greater strut depth in WT-stented
grafts than in KO-stented grafts. A significantybridization for miR-21
) low magnification and (C and E) areas under enhanced magnification
ions highlighted by the hatched areas are seen in murine stented
implantation, as are (B) MiR-21 probe and (D and F) areas under
ion corresponding to regions highlighted by the hatched areas.reduction in luminal area in WT mice compared with
miR-21 KO mice was also observed (Figures 4C and 4D,
Online Table 2). There were no apparent differences
in luminal, media, or total vessel area between WT
and miR-21 KO mice at baseline (before stent injury),
although an increased sample size would be need-
ed to confirm this observation (Online Table 3).
Furthermore, the total vessel area did not differ
significantly at 28 days (Figure 4E), and no differences
were observed in unstented vessels at baseline
(Online Table 3).
The neointimal lesions from miR-21 KO mice
contained significantly less a-actin–positive SMCs
(28  2.4% [n ¼ 8] vs. 14  3.7% [n ¼ 9]; p < 0.01)
(Figures 5A and 5B). Lesions in WT mice contained
50% more elastin than in KO mice (Figures 5C and 5D,
Online Table 2). No difference in cell proliferation was
observed after quantification of cells in the neointima
(Figures 5E and 5F, Online Table 2). We assessed vessel
reendothelialization and, importantly, found no sig-
nificant difference between miR-21 KO and WT mice
(91.0  3.9% vs. 88.7  2.9%, respectively) (Figures 5G
and 5H). No differences were observed at baseline
(i.e., unstented vessels) (Online Table 3).
To explore the mechanisms responsible for the
reduction in neointima formation in miR-21 KO mice,
proliferation and wound healing assays were per-
formed. The proliferative response of miR-21 KO SMC
was dramatically attenuated in response to platelet-
derived growth factor (PDGF) (Figure 6A), as was
migration in response to PDGF (Figures 6B and 6C).
To identify potential targets responsible for these
effects, we stimulated aortic SMC from miR-21 WT
and KO mice with PDGF (n ¼ 5) to elevate miR-21
levels (3.03  0.23-fold vs. controls; p < 0.01)
(Figure 6D). The messenger RNA levels of known
miR-21 targets with defined roles in SMC prolifera-
tion and migration were profiled. The expression of
programmed cell death protein 4 (PDCD4) and signal
transducer and activator of transcription 3 were
significantly reduced in aortic SMC from WT mice
after PDGF stimulation. These changes were not
observed in miR-21 KO cells stimulated with PDGF
(Figures 6E and 6F); however, further experiments
are required to determine whether repression of
these genes is direct or indirect via miR-21 regulation
in this setting.
MiR-21 KO mice contained greater numbers of
galactin-3þ (MAC-2) macrophages in the neointima
comparedwithWTmice (0.790.23%vs. 2.540.75%;
p < 0.05) (Figures 7A and 7B) and enhanced levels
of YM-1–positive macrophages, a validated murine
marker of the alternatively activated (M2) macro-
phage (1.93  0.54% vs. 0.50  0.21%; p < 0.01)
FIGURE 4 Effect of miR-21 Ablation on Neointimal Formation and ISR
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2319(Figures 7C and 7D). Thus, loss of miR-21 results in
altered inflammatory cell phenotype within injured
vessels. To investigate whether these effects were
derived from any hematological defect, before cell
recruitment to the vessel wall, the populations of
immune cells in both bone marrow and blood of WT
and miR-21 KO mice were examined (16). In bone
marrow, the percentage of cluster of differentiation
(CD) 3þ T cells was significantly reduced in miR-21 KO
mice, but neutrophils, monocytes, B cells, CD4þ, and
CD8þ T cells did not differ (Online Figures 3A and 3B).
In blood, miR-21 KO mice exhibited a significantly
reduced percentage of circulating Ly6cþhi monocytes
and CD3þ T cells (Figures 7E and 7F), potentially
indicating a reduced capacity to develop proin-
flammatory responses.
To investigate whether the absence of miR-21 leads
to altered macrophage differentiation, BMDMs from
WT and miR-21 KO mice were generated and treated
with either lipopolysaccharide (LPS) or interleukin
(IL)-4 in vitro to induce M1 and M2 polarization,
respectively. Both LPS and IL-4 significantly
up-regulated the expression of miR-21-3p and
miR-21-5p in WT macrophages (3.00  0.23-fold,
4.38  0.91-fold, 4.74  0.13-fold, and 4.88  0.7-fold,
respectively; p < 0.05), indicating that inflammatory
mediators can modulate the expression of miR-21
(Figure 8A). At baseline, unstimulated (M0, non-
polarized) miR-21 KO macrophages had significantly
higher levels of peroxisome proliferator–activated
receptor (PPAR)-g expression (M2 polarization
marker) than WT cells (p < 0.01) (Figure 8B). After
activation with LPS, expression of nitric oxide syn-
thase (an M1 marker) was significantly reduced in
miR-21 KO versus WT macrophages (Figure 8C). In
addition, the ratio of messenger RNA expression of
nitric oxide synthase, compared with arginase 1 (an
M2 marker), was significantly higher in WT than miR-
21 KO macrophages treated with LPS (20.6  6.52-fold
vs. 2.7  1.24-fold; p < 0.001) (Figure 8D). Flow
cytometric analysis demonstrated that after activa-
tion with LPS, CD69 was significantly reduced in miR-
21 KO versus WT LPS-treated macrophages (1.8-fold;
p < 0.05) (Figure 8E). However, all other markers
examined by using flow cytometry (major histocom-
patibility complex-II, CD11c, CD86, CD206, and Toll-
like receptor-2) were not significantly different in
either LPS- or IL-4–treated WT or miR-21 KO BMDM
(Online Figure 4). The levels of several proin-
flammatory mediators were significantly reduced
from LPS-stimulated macrophages of miR-21 KO
compared with WT mice: IL-1a, IL-1b, IL-6, IL-12, tu-
mor necrosis factor-a, and macrophage inflammatory
protein-1a (Figure 8F). In addition, the IL-12/IL-10ratio for LPS-stimulated miR-21 macrophages was
almost double that of KO macrophages (24 vs. 13).
To address whether miR-21 KO macrophages had
a reduced capacity to infiltrate and migrate into
vascular lesions after injury, we studied BMDM
migration through Matrigel-coated transwell inserts
containing 8-mm pores (Sigma, United Kingdom).
These experiments showed that both BMDM iso-
lated from WT and miR-21 KO mice had the same
capacity to migrate through a matrix membrane in
response to monocyte chemoattractant protein-1
(Figure 8G).
FIGURE 5 Cellular Analysis of Murine Lesions
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FIGURE 6 In Vitro Analysis of miR-21 SMC
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2321DISCUSSION
We report for the first time miRNA patterns associated
with delayed arterial healing and neointima forma-
tion after stenting (Central Illustration). Aberrantly
expressed miRNA lead and “passenger” strands asso-
ciated with 7- and 28-day time points were identified.Of particular interest, the stem loop of miR-21,
including lead (miR-21-5p) and passenger (miR-21-3p)
strands, was up-regulated in both the BMS and
DES groups compared with controls. Further experi-
ments highlighted that loss of the miR-21 stem
loop in KO mice blocked neointimal formation
through effects on SMC proliferation and migration,
FIGURE 7 Inflammatory Cells in Neointimal Lesions and Blood of miR-21 KO Mice
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FIGURE 8 In Vitro Altered Inflammatory Response in miR-21–Deficient Macrophages
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CENTRAL ILLUSTRATION Role of miRNA in ISR
McDonald, R.A. et al. J Am Coll Cardiol. 2015; 65(21):2314–27.
Although drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR), they delay vascular healing and are associated with a chronic inflammatory
response, which involves micro–ribonucleic acids (miRNAs). In pig, mouse, and in vitro models, miR-21 promotes vascular inflammation and remodeling after stenting
and may be a therapeutic target to enhance wound healing after vascular injury. BMS ¼ bare-metal stent(s); FACS ¼ fluorescence-activated cell sorting; IL ¼ interleukin;
KO ¼ knockout; LPS ¼ lipopolysaccharide; PDGF ¼ platelet-derived growth factor; RT-PCR ¼ real-time polymerase chain reaction; SMC ¼ smooth muscle cell;
TNF ¼ tumor necrosis factor; WT ¼ wild type.
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tion. A causal network analysis was performed of miR-
21-3p and miR-21-5p targets to determine whether
these miRNAs affect the inflammatory networks
associated with vascular injury. Despite a relatively
small overlap of predicted genes, pathways associated
with tumor necrosis factor-a and IL-1 were 1 of the
top-ranking regulatory networks (Online Figure 5);
this finding may be relevant because both of these
cytokines play prominent roles in neointima forma-
tion (17,18).
MiR-21 KO mice exhibited reduced SMC deposi-
tion, neointima formation, and an altered inflam-
matory phenotype, resulting in enhanced levels of
anti-inflammatory M2 macrophages in response to
vascular injury and stenting, with no effect on
endothelial regeneration. Subsequent profiling of
immune cell populations in the blood of miR-21 KO
mice demonstrated reduced numbers of Ly6cþhicells, a cell type that can differentiate into M1 mac-
rophages after tissue infiltration. This finding sug-
gests that miR-21 KO mice have a reduced capacity to
develop an M1 inflammatory phenotype in response
to injury. We also found reduced total CD3þ T-cell
counts in the bone marrow and blood of the miR-21
KO. Recently, it has been reported that miR-21 can
modulate T-cell responses, including alterations in
cytokine production and apoptosis rates (19–21).
T cells are already known to contribute to the in-
flammatory response after coronary artery stenting
(22); thus, the absence of miR-21 in T cells likely
contributes to the altered inflammatory responses
and reduced in-stent stenosis seen in miR-21 KO.
In support of the altered inflammatory responses
in vivo, our BMDM experiments revealed that miR-21
KO macrophages contain enhanced baseline levels of
PPAR-g, a well-characterized M2 macrophage marker,
and a reduced ratio of nitric oxide synthase/arginase
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23251 (M1/M2 markers). These findings are particularly
relevant in the setting of inflammatory vascular dis-
ease because numerous studies suggest that PPAR-g
activation can curtail the inflammatory response.
Activation of PPAR-g in human macrophages reduces
matrix metallopeptidase 9 activity and inhibits ex-
pression of IL-1b, IL-6, and tumor necrosis factor-a
(23–25). Furthermore, several groups have reported
that PPAR-g agonists inhibit atherosclerosis devel-
opment and reduce inflammatory markers in apoli-
poprotein E KO mice (26,27). Furthermore, miR-21
KO macrophages exhibited a reduced capacity to
secrete proinflammatory mediators such as IL-1,
tumor necrosis factor-a, macrophage inflammatory
protein-1, IL-6, and IL-12 in response to LPS, a
substance known to stimulate the inflammatory
M1 macrophage phenotype. However, a defective
response to LPS does not necessarily mean altered
polarization and may simply reflect, for example,
defective CD14 expression. Further phenotyping of
surface receptors from BMDM also showed reduced
expression of CD69 in miR-21 KO mice. A CD69
deficiency may contribute to reduced inflammatory
cytokine secretion, as previous studies have reported
that CD69 activation mediates numerous inflamma-
tory processes such as nitric oxide production and
release of tumor necrosis factor-a from murine
macrophages and T cells (28,29). Thus, loss of miR-21
may accelerate wound healing and resolution of
the inflammatory response after vascular injury and
stenting, events that could reduce the incidence of
late stent thrombosis.
It is important to note that we used human arrays
in the porcine samples to identify miRNAs that would
extrapolate to the pathology in the clinical setting. It
is possible that a proportion of miRNAs may be un-
derrepresented due to the sequence variation or
chromosomal locations between pig and human.
We identified an almost 20-fold up-regulation of miR-
21-3p after stenting with BMS and DES. Our subse-
quent experiments in BMDM demonstrated that both
miR-21-3p and miR-21-5p were up-regulated in
response to LPS, which induces classical macrophage
polarization (M1). In combination with reduced
inflammatory cytokine release from miR-21 KO mac-
rophages, these results suggest that miR-21-3p and
miR-21-5p may both play a pathological role in
macrophage activation in response to inflammatory
stimuli.
Currently available DES directly target SMC pro-
liferation to prevent neointima formation. We
observed that miR-21 plays a prominent role in SMC
proliferation and migration in response to vascular
injury, consistent with other studies (30,31). AorticSMC isolated from miR-21 KO mice had a reduced
capacity to migrate and proliferate in response to
PDGF, an important observation because novel DES
must retain the antiproliferative effect on SMC accu-
mulation to maintain their clinical efficacy. These
findings are consistent with previous reports
demonstrating that pharmacological or genetic
knockdown of miR-21 reduces SMC proliferation and
neointima formation after balloon injury or vein
grafting (30–33). Several of these reports suggest that
miR-21 mediates a beneficial effect on SMC prolifer-
ation and neointima, at least in part, via inhibition of
phosphatase and tensin homolog.
We also found that the levels of PDCD4 were sup-
pressed after PDGF exposure in WT mice. Impor-
tantly, the levels of PDCD4 were increased in miR-21
KO mice, suggesting that PDCD4 is modulated after
exposure to PDGF and plays a role in SMC prolifera-
tion and migration, effects repressed in miR-21 KO
SMCs. In concordance with these findings, previous
studies suggest that PDCD4 is down-regulated after
vascular injury, and overexpression of PDCD4 with
adenoviral vectors increases apoptosis and reduces
SMC proliferation (34).
STUDY LIMITATIONS. Although the present study
demonstrates that miR-21 play a prominent role in the
pathology of in-stent restenosis, it is important to
note that these studies are based on data from pre-
clinical animal models of restenosis. Although our
results in miR-21 knockout mice demonstrate that
loss of miR-21 reduces in-stent restenosis and in-
flammatory cell function, it is important to note that
these defects are present before vascular injury, these
deficiencies may alter the response to injury in these
mice. In order to demonstrate that these finding have
efficacy in the clinic, further studies are required to
demonstrate that pharmacological knockdown ofmiR-
21 or miR-21 targets can inhibit neointimal formation
and vessel inflammation from current drug-eluting
stent platforms. Furthermore, detailed pharmacoki-
netic profiling would be needed to demonstrate an
effect elution profile of antimiR-21 therapy, without
any off-target effect.
CONCLUSIONS
The miR-21 stem loop plays an important role in
SMC and macrophage activation after vascular
injury. Our findings in the murine model of ISR
revealed that loss of miR-21 attenuates neointima
formation and macrophage activation, resulting in
a less inflammatory phenotype. These findings sug-
gest that miR-21 modulation could enhance wound
PERSPECTIVES
COMPETENCY IN PATIENT CARE: DES reduce
in-stent restenosis after percutaneous coronary
intervention but are associated with a greater risk of
stent thrombosis due to delayed arterial healing that
is characterized histologically by incomplete reendo-
thelialization and persistent fibrin and inflammatory
cell deposition. An array of microRNA molecules are
involved in the inflammatory processes driving the
cellular response to vascular injury, and genetic KO of
the miR-21 stem loop attenuates neointimal formation
after arterial stenting in mice.
TRANSLATIONAL OUTLOOK: Future investiga-
tions should seek to determine whether local antimiR
to knockdown miR-21 levels delivered directly from
drug-eluting stents could reduce vessel inflammation
and neointima formation and reduce the risk of both
restenosis and stent thrombosis.
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2326healing and resolve the inflammatory response,
effects that could improve the clinical efficacy
of currently available DES. The miR-21 axis warr-
ants further investigation as a therapeutic target in
the setting of stent-induced inflammatory vascular
disease. Lineage-restricted knockouts maybe re-
quired to unravel the complex role of miR-21 in this
setting.
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